Market Trends of Hepatitis C Industry
Antiviral Drugs Segment is Expected to Hold a Major Share in the Hepatitis C Market
- Antiviral drugs are one class of antimicrobials used for treating hepatitis C. These medications usually work by prohibiting the multiplication of the HCV virus. The segment's growth is attributed to the high burden of hepatitis C infection and the growing adoption and advantages of antiviral drugs over other treatment modalities.
- For instance, according to an article published by the American Association for the Study of Liver Diseases in September 2022, the estimated national prevalence rate of HCV infection in India was 0.32%, with 44.2 million HCV-positive individuals making up a significant portion of the worldwide HCV burden. Thus, with the high burden of hepatitis C, the demand for antiviral drugs is expected to increase, leading to segmental growth.
- Furthermore, according to the World Health Organization (WHO) update in June 2022, antiviral medicines cure more than 95% of hepatitis C infections. WHO recommends therapy with pan-genotypic direct-acting antivirals (DAAs) for all adults, adolescents, and children down to 3 years of age with chronic hepatitis C infection. In 2022, WHO included new recommendations for treating adolescents and children using the same pan-genotypic treatments for adults. Thus, with the increased adoption of antiviral therapies over other treatment modalities, the segment is anticipated to grow over the coming years.
- Thus, owing to the factors above, the usage of antiviral drugs is expected to grow significantly during the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Hold a Significant Share in the Hepatitis C Market
- Due to an increase in hepatitis C infections and the commercial availability of hepatitis drugs in the region, North America is expected to hold a significant market share in the hepatitis C market. For instance, according to an article published by the American Hospital Association, in August 2022, over 2 million United States adults have hepatitis C virus infection each year. Infections are increasing by about 60,000 annually due to the opioid epidemic. Thus, with an increase in hepatitis C infection, the demand for its diagnosis and treatment is likely to increase, ultimately boosting the market growth in the region.
- Furthermore, the presence of key market players, growing awareness programs, and the introduction of newer drugs and tests in the region bolster the market's growth in the North American region. For instance, in February 2022, the Task Force for Global Health sponsored a clinical trial to assess the outcomes of hepatitis C-affected mother-infant pairs exposed to direct-acting antivirals (DAAs) during pregnancy within a global clinical case registry. Additionally, in October 2021, AbbVie Inc. initiated a clinical trial in the United States to assess the adversative events and modifications in disease activity in adolescent and adult participants with acute hepatitis C virus (HCV) infection on treatment with oral tablets of Glecaprevir (GLE)/Pibrentasvir (PIB). Such instances are likely to favor the market growth in the region.
- Thus, due to the abovementioned factors, North America is anticipated to witness notable growth over the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
